Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

Blinatumomab can induce a complete haematological remission in patients in 46.6% with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) resulting in a survival benefit when compared with chemotherapy. Only bone marrow blast counts before therapy have shown a weak prediction of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Duell, J, Dittrich, M, Bedke, T, Mueller, T, Eisele, F, Rosenwald, A, Rasche, L, Hartmann, E, Dandekar, T, Einsele, H, Topp, M S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629361/
https://www.ncbi.nlm.nih.gov/pubmed/28119525
http://dx.doi.org/10.1038/leu.2017.41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629361/
https://www.ncbi.nlm.nih.gov/pubmed/28119525
http://dx.doi.org/10.1038/leu.2017.41

Ejemplares similares